A discovery by Oak Ridge National Laboratory researchers may aid the design of materials that better manage heat.
A new technology for rare-earth elements chemical separation has been licensed to Marshallton Research Laboratories, a North Carolina-based manufacturer of organic chemicals for a range of industries.
Energy Secretary Jennifer Granholm visited ORNL on Nov. 22 for a two-hour tour, meeting top scientists and engineers as they highlighted projects and world-leading capabilities that address some of the country’s most complex research and technical challenges.
A team led by the U.S. Department of Energy’s Oak Ridge National Laboratory demonstrated the viability of a “quantum entanglement witness” capable of proving the presence of entanglement between magnetic particles, or spins, in a quantum material.
Researchers at Oak Ridge National Laboratory have developed a method of adding nanostructures to high-entropy metal alloys, or HEAs, that enhance both strength and ductility, which is the ability to deform or stretch
Matthew Ryder has been named an emerging investigator by the American Chemical Society journal Crystal Growth and Design. The ACS recognized him as “one of an emerging generation of research group leaders for his work on porous materials design.”
Researchers at ORNL have developed a robotic disassembly system for spent electric vehicle battery packs to safely and efficiently recycle and reuse critical materials while reducing toxic waste.
ASM International recently elected three researchers from ORNL as 2021 fellows. Selected were Beth Armstrong and Govindarajan Muralidharan, both from ORNL’s Material Sciences and Technology Division, and Andrew Payzant from the Neutron Scattering Division.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.